Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 1/20 | 0.41 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711738 | 1.00 | CPB2 (0.47) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL1711732 | 1.00 | CPB2 (0.47) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL1711321 | 1.00 | CPB2 (0.47) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| Hydrochloric Acid SCHEMBL11366046 | 0.99 | CPB2 (0.47) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL31257001 | 0.95 | CPB2 (0.45) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL30284335 | 0.95 | CPB2 (0.45) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL30973961 | 0.93 | FOLH1 (0.56) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL29782763 | 0.92 | FOLH1 (0.51) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL1711313 | 0.92 | FOLH1 (0.54) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL1711315 | 0.92 | FOLH1 (0.54) | CPB2FOLH1ERAP2ERAP1LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027224-A1 | ANTIBODY-DRUG CONJUGATES TARGETING CDH3 AND PREPARATION METHODS AND USES THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-29 | — | — | US | claimed |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | claimed |
| EP-4674840-A1 | CHEMICAL COUPLING LINKER AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2026-01-07 | — | — | EP | claimed |
| EP-4631952-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-10-15 | — | — | EP | claimed |
| EP-4603487-A1 | HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-08-20 | — | — | EP | claimed |
| EP-4603109-A1 | ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-08-20 | — | — | EP | claimed |
| WO-2024235130-A9 | POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-26 | — | — | WO | claimed |
| CN-120202203-A | Heterocyclic compounds, their preparation and use | 四川科伦博泰生物医药股份有限公司 | 2025-06-24 | — | — | CN | claimed |
| CN-120202027-A | Antibody drug conjugate, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2025-06-24 | — | — | CN | claimed |
| WO-2024235134-A9 | CONJUGATE HAVING TARGETING EFFECT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-19 | — | — | WO | claimed |
| WO-2024149093-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-07-18 | — | — | WO | claimed |
| WO-2024114531-A1 | HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-06-06 | — | — | WO | claimed |
| WO-2024114318-A1 | DRUG LINKER COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-06-06 | — | — | WO | claimed |
| WO-2024114523-A1 | ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-06-06 | — | — | WO | claimed |
| CN-118105508-A | Medicinal linker compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-05-31 | — | — | CN | claimed |
| EP-4271387-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCS CONTAINING AND USE THEREOF | Immunext, Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| WO-2023202654-A1 | COMPOUND AND USE THEREOF | 同宜医药（苏州）有限公司 | 2023-10-26 | — | — | WO | claimed |
| CN-116589528-A | Lumbricus guangdong characteristic peptide and application thereof | 江阴天江药业有限公司 | 2023-08-15 | — | — | CN | claimed |
| WO-2022150637-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF | IMMUNEXT, INC. (US) | 2022-07-14 | — | — | WO | claimed |
| US-4257940-A | Valylleucyllysine derivatives, process for producing same and method for measuring activity of enzymes using same | TORII & CO., LTD. (JP) | 1981-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027224-A1 | ANTIBODY-DRUG CONJUGATES TARGETING CDH3 AND PREPARATION METHODS AND USES THEREOF | H1-3, H1-4, H1-2 | CPB2 3834/4885FOLH1 488/4885ERAP2 4684/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | CPB2 1040/4885FOLH1 1/4885ERAP2 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.